



30 July 2025

Zelira advances diabetic neuropathy study and bolsters HOPE® 1 SPV funding



QUARTERLY ACTIVITIES REPORT FOR Q4 FY2025
ASX ANNOUNCEMENT

Key Highlights



Publication of ZLT-L-007 IRB Approved Observational Study

- Study demonstrates that ZLT-L-007 significantly outperforms Lyrica® (Pregabalin) in reducing pain intensity, improving sleep, and alleviating neuropathic symptoms.



Full conversion of US\$3.25 million convertible notes, including accrued interest, into equity in HOPE® 1 SPV

- Funding supports key clinical and regulatory development of HOPE® 1, removes debt obligations, and strengthens SPV capital structure.



Post reporting period, Zelira entered into a non-dilutive loan agreement to support R&D initiatives and increase its FY25 R&D tax incentive claim

Zelira Therapeutics Ltd (ASX:ZLD, OTCQB:ZLDAF), a global leader in the development and commercialisation of clinically validated cannabinoid-based medicines, is pleased to provide its quarterly activities report and Appendix 4C for the three months ended 30 June 2025 (Q4 FY2025).



Commenting on the operational progress in Q4 FY2025, Global Managing Director & CEO, Dr Oludare Odumosu said:

Our continued progress reflects Zelira's ability to execute on our clinical and commercial strategy. The published results from our ZLT-L-007 study affirm its therapeutic potential in diabetic neuropathy and represent the first clinical signal from a broader pipeline of cannabinoid-based assets.

We are particularly encouraged by ZLT-L-007's performance against Lyrica®, reinforcing our confidence as we move towards formal FDA trials. Simultaneously, the full conversion of US\$3.25 million in convertible notes into equity enhances our capital structure, eliminates debt obligations, and strengthens our position ahead of upcoming clinical milestones.

As we move forward, we remain focused on optimising our Zyraydi™ technology, a next-generation delivery platform to be deployed across our HOPE® and Zenivol® products - while progressing a repeatable model of clinical validation, asset-level capitalisation, and commercial optionality. This positions Zelira to unlock value across multiple therapeutic verticals and geographies.

Full study publication of IRB approved observational study demonstrating promising efficacy and safety of ZLT-L-007 compared to Lyrica® (Pregabalin) in diabetic neuropathy

In May, Zelira announced the publication of its clinical study report titled *"Comparative Evaluation of ZLT-L-007, a Proprietary Cannabinoid-Based Therapy, and Pregabalin (Lyrica®) for Pain Reduction in Diabetic Neuropathy."*

The IRB-approved, 12-week observational study randomised 60 adults with diabetic neuropathy into three groups: Lyrica® monotherapy, ZLT-L-007 monotherapy, and combination therapy. The primary endpoint was change in daily pain numeric rating scale (NRS), assessed at Days 30, 60, and 90.

The results of the study demonstrate ZLT-L-007 as a highly promising cannabinoid-based therapy that relieved pain more effectively than

Lyrica® while addressing symptom complexity, sleep disturbance, emotional burden, and overall quality of life. Additionally, these encouraging Phase I outcomes provide a foundation for upcoming Phase II randomised, double-blind, placebo-controlled trials to confirm ZLT-L-007's therapeutic potential.

Data generated from the study will support future regulatory submissions, inform the design of subsequent clinical trials, and strengthen Zelira's commercialisation pathway.



Full conversion of convertible notes into equity in HOPE® 1 SPV

In April, Zelira successfully completed the full conversion of USD \$3.25 million in Convertible Notes, along with USD \$326,876 in accrued interest, into equity within the Zelira-HOPE 1 SPV. This conversion significantly enhances the SPV's capital structure, positioning Zelira strongly for the next phase of its institutional capital raise.

Funds from this raise will be dedicated to supporting the ongoing FDA clinical trial program for HOPE® 1, initially focused on treating Autism Spectrum Disorder in patients with Phelan-McDermid Syndrome.

R&D loan facility secured

Post reporting period, Zelira entered into a non-dilutive loan agreement with RH Capital Finance Co., LLC (Rocking Horse Capital), securing a \$650,000 facility. The loan is secured against the anticipated R&D Tax incentive rebate for FY25 and will be used to support the advancement of the HOPE® SPV clinical trial and general working capital. This funding will also assist the Company in increasing its eligible R&D expenditure to optimise the FY25 tax incentive claim.

Operational activities

The performance in Q4 FY2025 reflects Zelira's continuous focus on its clinical validation strategy.

Financial snapshot

The Company's net cashflow used in operations for Q4 FY2025 was \$384k. Operational expenses mainly comprised:

- Research and development of \$46k, down from \$389k in Q3 FY2025 reflecting costs associated with the HOPE® 1 trial preparations due to timing of payments and invoicing
- Advertising and marketing of \$2k, down from \$53k in Q3 FY2025 for due to timing of payments

- Staff costs of \$191k, down from \$315k in Q3 FY2025 due to timing of payments
- Administrative and corporate costs of \$82k, down from \$725k in Q3 FY2025 due to timing of payments
- Variations in costs reflect the timing of payments

Listing Rule 4.7C.3

In item 6 of the attached Appendix 4C, payments to related parties comprised of \$80k Director Services.

As at 30 June 2025, the Company had a cash position of \$7k.

Strategy and outlook

Clinical validation and product development remains core to Zelira's growth plans. Zelira is focused on its clinical activities to develop and evaluate the efficacy, safety and tolerability of its proprietary formulations and products.

FDA clinical trials will be an important next step for two key patent-protected products:

- HOPE® 1: Via the establishment of the HOPE® 1 SPV, Zelira has successfully gained the resources to start the FDA clinical trials for HOPE® 1, a patent-protected autism treatment. Zelira has commenced the FDA trial process with appointed CRO iNGENU and has completed the Target Product Profile.
- Diabetic Nerve Drug Treatment ZLT-L-007: Following the receipt of the positive top-line results from the IRB approved diabetic drug trial, demonstrating ZLT-L-007 outperformed Pharma drug Lyrica®, Zelira is evaluating the further progression of ZLT-L-007 into formal FDA clinical trials.

This announcement has been approved and authorised for release by the board of Zelira Therapeutics Limited.



For further information
please contact

Company

Dr Oludare Odumosu
Managing Director & CEO
☎ +1 909 855 0675
✉ oodumosu@zeliratx.com

Australia

Level 3, 101 St Georges Terrace
Perth WA 6000, AUSTRALIA
☎ +61 8 6558 0886
Fax: +61 8 6316 3337
✉ enquiries@zeliratx.com

www.zeliratx.com

ACN 103 782 378

Investors

Rebecca Culbertson
Executive Director, Automic Group
☎ +61 400 955 295
✉ rebecca.culbertson@automicgroup.com.au

USA

5110 Campus Drive, Suite 150
Plymouth Meeting, PA 19462
United States Of America
☎ +1 484 630 0650

Zelira Therapeutics Ltd (ASX:ZLD,

OTCQB:ZLDAF) Zelira is a leading global biopharmaceutical company in the research, development and commercialisation of clinically validated cannabinoid-based medicines. Zelira owns a portfolio of proprietary revenue generating products and a pipeline of candidates undergoing clinical development positioned to enter global markets. The Company is focused on developing and clinically validating branded cannabinoid-based medicines in its prescription [Rx] business for the treatment of a variety of medical conditions including insomnia, autism and chronic noncancer pain as well as offering over the counter [OTC] products.

Zelira has established a special purpose vehicle (SPV) to conduct FDA Phase 1, Phase 2 and Phase 3 clinical trials for Zelira's proprietary and patent protected HOPE® 1. Zelira has contributed to the SPV its HOPE® 1 product, IP and real-world data for 55% equity ownership of the SPV. Cash investors will contribute a total of circa US\$35 million to fund the SPV and US FDA trials for HOPE® 1 in exchange for a cumulative equity interest of 45% of the SPV. Zelira will manage the SPV as part of its business platform. The SPV has appointed iGENū CRO Pty Ltd (iGENū) as its Contract Research Organisation (CRO) to lead the clinical validation and regulatory registration of the study product with the US FDA through the submission of an Investigative New Drug (IND) application.

In May 2023, Zelira completed an IRB approved strategically designed multi-arm, head-to-head study targeting diabetic nerve pain. The clinical trial included a comprehensive comparison against the widely recognised and highly successful

multi-billion dollar revenue generating drug Lyrica® (Pregabalin). With the findings underscoring the exceptional efficacy of our treatments in managing pain, with ZLT-L-007 demonstrating the most substantial reduction in pain severity, particularly at the 60-day and 90-day follow-up periods. Zelira has developed Enhanced Distillate Capture and Dissolution Matrix (EDCDM) technology under the brand name Zyraydi™, that solves the problem of non-uniformity and separation of cannabinoid from powder bed, opening new ways to develop pharmaceutical grade solid oral dosage forms such as capsules and tablets. Zelira will be assessing opportunities for commercialisation of this technology.

Zelira's Rx business generates revenue from its proprietary medication, HOPE. The Company has two proprietary formulations under the HOPE® brand that are generating revenue in Australia, Washington, D.C., Pennsylvania and Louisiana. Zelira will also be expanding commercialisation of ZENIVOL® – the world's first clinically validated cannabinoid drug for treatment of chronic insomnia into Germany via its German commercialisation partner Adjupharm GmbH following recent approval from German regulatory authority BfArM. Zelira's OTC products in the oral and dermatology health care sectors are also generating revenue. Zelira, in partnership with SprinJeneCBD, launched a full line of oral care products, currently generating revenue in the US. Zelira also launched in 2021 the RAF FIVE™ brand, which consists of five OTC acne treatment products using a proprietary formulation incorporating cannabidiol (CBD).

For further information, please visit: zeliratx.com



Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

Zelira Therapeutics Limited

ABN

27 103 782 378

Quarter ended ("current quarter")

30 JUNE 2025

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (12 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	3	23
1.2 Payments for		
(a) research and development	(46)	(946)
(b) product manufacturing and operating costs	(3)	(11)
(c) advertising and marketing	(2)	(127)
(d) leased assets	(55)	(311)
(e) staff costs	(191)	(1,494)
(f) administration and corporate costs	(82)	(1,710)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	-	-
1.5 Interest and other costs of finance paid	(8)	(330)
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	-	1,153
1.8 Other (provide details if material)	-	-
1.9 Net cash from / (used in) operating activities	(384)	(3,753)
2. Cash flows from investing activities		
2.1 Payments to acquire or for:		
(a) entities	-	-
(b) businesses	-	-
(c) property, plant and equipment	-	-
(d) investments	-	-
(e) intellectual property	-	-
(f) other non-current assets	-	-

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (12 months) \$A'000
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	Net cash from / (used in) investing activities	-	-

3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	25	25
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	(28)
3.5	Proceeds from borrowings	-	2,098
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material) – HOPE SPV funding – refer Note 7	-	1,094
3.10	Net cash from / (used in) financing activities	25	3,189

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	363	586
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(384)	(3,753)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	-	-

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (12 months) \$A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	25	3,189
4.5	Effect of movement in exchange rates on cash held	3	(15)
4.6	Cash and cash equivalents at end of period	7	7

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	(2)	354
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	9	9
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	7	363

6.	Payments to related parties of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	80
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-
<p><i>Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.</i></p> <p><u>Director Services</u> Executive Board Remuneration - \$80,000</p>		

7.	Financing facilities <i>Note: the term "facility" includes all forms of financing arrangements available to the entity.</i> <i>Add notes as necessary for an understanding of the sources of finance available to the entity.</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000															
7.1	Loan facilities	2,098	2,098															
7.2	Credit standby arrangements	-																
7.3	Other (please specify) Hope SPV convertible notes	5,175	5,175															
7.4	Total financing facilities	7,273	7,273															
7.5	Unused financing facilities available at quarter end	-																
7.6	Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.																	
	Loan facilities <table border="1" style="width: 100%; border-collapse: collapse; margin-top: 10px;"> <tr> <td style="width: 30%;">Lender:</td> <td style="width: 30%;">Mr Osagie Imasogie</td> <td style="width: 40%;">RH Capital Finance Co., LLC</td> </tr> <tr> <td>Amount:</td> <td>US\$1,400,000</td> <td>A\$650,000</td> </tr> <tr> <td>Interest Rate:</td> <td>20.0% per annum paid monthly</td> <td>17% per annum</td> </tr> <tr> <td>Commencement date</td> <td>28 June 2024</td> <td>24 July 2025</td> </tr> <tr> <td>Maturity</td> <td>28 June 2026</td> <td>30 November 2025</td> </tr> </table>			Lender:	Mr Osagie Imasogie	RH Capital Finance Co., LLC	Amount:	US\$1,400,000	A\$650,000	Interest Rate:	20.0% per annum paid monthly	17% per annum	Commencement date	28 June 2024	24 July 2025	Maturity	28 June 2026	30 November 2025
Lender:	Mr Osagie Imasogie	RH Capital Finance Co., LLC																
Amount:	US\$1,400,000	A\$650,000																
Interest Rate:	20.0% per annum paid monthly	17% per annum																
Commencement date	28 June 2024	24 July 2025																
Maturity	28 June 2026	30 November 2025																

8.	Estimated cash available for future operating activities	\$A'000
8.1	Net cash from / (used in) operating activities (item 1.9)	(384)
8.2	Cash and cash equivalents at quarter end (item 4.6)	7
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	7
8.5	Estimated quarters of funding available (item 8.4 divided by item 8.1) <i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>	-
8.6	If item 8.5 is less than 2 quarters, please provide answers to the following questions: 8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
	Answer: Yes	

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer: Post reporting period, Zelira entered into a non-dilutive loan agreement with RH Capital Finance Co., LLC (Rocking Horse Capital), securing a \$650,000 facility. The loan is secured against the anticipated R&D Tax incentive rebate for FY25 and will be used to support the advancement of the HOPE® SPV clinical trial and general working capital. This funding will also assist the Company in increasing its eligible R&D expenditure to optimise the FY25 tax incentive claim.

The Company has secured a \$1 million At-the-Market Facility (ATM) Agreement with Securities Vault Pty Ltd to support its growth objectives. The ATM facility provides Zelira with up to \$1 million of standby equity capital over the next 12 months enabling additional flexibility for the Company to conduct capital raising activities over time, closely aligning capital needs with operational activities.

Furthermore, the Company is substantially progressing its funding efforts its HOPE SPV to close the remaining balance of the circa US\$32 million capital raise to fund HOPE® 1 trials in the USA. Zelira expects to have subsequent rounds of closings this quarter from its continuing fund-raising efforts to support the HOPE® 1 formal FDA clinical program. The SPV funding includes working capital for the Company to enable it to continue its operations and to meet its business objectives.

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer: Refer above.

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date:30 July 2025.....

Authorised by:By the Board.....
 (Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the

[*name of board committee – eg Audit and Risk Committee*]. If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".

5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.